{"title":"BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation","public_updated_at":"2016-05-10T14:31:14Z","details":{"metadata":{"therapeutic_area":["cancer","haematology","immunosuppression-transplantation"],"bulk_published":false,"first_published_at":"2016-05-10T14:31:14Z","document_type":"drug_safety_update"},"change_history":[{"public_timestamp":"2016-05-10T14:31:14Z","note":"First published."}],"body":[{"content_type":"text/html","content":"\n<div class=\"call-to-action\">\n<p>Advice for healthcare professionals:</p>\n\n<ul>\n  <li>Test patients for infection with hepatitis B virus (<abbr title=\"hepatitis B virus\">HBV</abbr>) before starting treatment with BCR-ABL tyrosine kinase inhibitors</li>\n  <li>Consult experts in liver disease and in the treatment of <abbr title=\"hepatitis B virus\">HBV</abbr> before starting treatment with BCR-ABL tyrosine kinase inhibitors in patients with positive <abbr title=\"hepatitis B virus\">HBV</abbr> serology (including those with active disease) and for patients who test positive for <abbr title=\"hepatitis B virus\">HBV</abbr> during treatment</li>\n  <li>Patients who are carriers of <abbr title=\"hepatitis B virus\">HBV</abbr> who require treatment with BCR-ABL tyrosine kinase inhibitors should be closely monitored for signs and symptoms of active <abbr title=\"hepatitis B virus\">HBV</abbr> infection throughout treatment and for several months after stopping</li>\n  <li>Suspected adverse drug reactions to BCR-ABL tyrosine kinase inhibitors should be <a rel=\"external\" href=\"http://www.mhra.gov.uk/yellowcard\">reported to us on a Yellow Card</a></li>\n</ul>\n</div>\n\n<p>BCR-ABL tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, and ponatinib) are used in the treatment of chronic myeloid leukaemia or Philadelphia chromosome positive acute lymphoblastic leukaemia. Full details of authorised indications are given in individual Summaries of Product Characteristics.<sup id=\"fnref:1\"><a href=\"#fn:1\" class=\"footnote\">1</a></sup></p>\n\n<h2 id=\"cases-of-hbv-reactivation\">Cases of <abbr title=\"hepatitis B virus\">HBV</abbr> reactivation</h2>\n\n<p>An EU-wide review has shown that cases of <abbr title=\"hepatitis B virus\">HBV</abbr> reactivation can occur in patients who are chronic carriers of the virus after they have received a BCR-ABL tyrosine kinase inhibitor. Some cases resulted in acute liver failure or fulminant hepatitis, leading to liver transplantation or death. The review assessed cases from clinical studies and cases of suspected adverse drug reactions reported by healthcare professionals and in the literature.</p>\n\n<p>Case reports suggest that <abbr title=\"hepatitis B virus\">HBV</abbr> reactivation may occur at any time during treatment with a BCR-ABL tyrosine kinase inhibitor. Some patients had a history of hepatitis B, whereas for others the serological status at baseline was unknown. On <abbr title=\"hepatitis B virus\">HBV</abbr> reactivation, an increase in viral load or positive serology was diagnosed.</p>\n\n<p>The risk of <abbr title=\"hepatitis B virus\">HBV</abbr> reactivation is considered a class effect of BCR-ABL tyrosine kinase inhibitors; however, the mechanism and frequency of virus reactivation during exposure are currently unknown.</p>\n\n<h2 id=\"further-information\">Further information</h2>\n\n<p><a rel=\"external\" href=\"https://assets.digital.cabinet-office.gov.uk/media/5731b42be5274a037b000005/tyrosine_kinase_inhibitors_DHPC_sent_11_April_2016.pdf\">Letter sent to healthcare professionals</a> 11 April 2016 </p>\n\n<p>EU Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on <a rel=\"external\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/PRAC_recommendation_on_signal/2016/02/WC500202306.pdf\">updates to product information for BCR-ABL tyrosine kinase inhibitors</a></p>\n\n<p>Article citation: Drug Safety Update vol 9 issue 10, May 2016: 1.</p>\n\n<div class=\"footnotes\">\n  <ol>\n    <li id=\"fn:1\">\n      <p>Summaries of Product Characteristics are available on the <a rel=\"external\" href=\"http://www.ema.europa.eu/ema/\">European Medicines Agency website</a> for dasatinib, nilotinib, bosutinib, and ponatinib, and on the <a rel=\"external\" href=\"http://www.mhra.gov.uk/spc-pil/?secLevelIndexChar=Im%20-%20Ip#retainDisplay\">MHRA website</a> for imatinib. <a href=\"#fnref:1\" class=\"reversefootnote\">&#8617;</a></p>\n    </li>\n  </ol>\n</div>\n"},{"content_type":"text/govspeak","content":"$CTA\r\nAdvice for healthcare professionals:\r\n\r\n*  Test patients for infection with hepatitis B virus (HBV) before starting treatment with BCR-ABL tyrosine kinase inhibitors\r\n*  Consult experts in liver disease and in the treatment of HBV before starting treatment with BCR-ABL tyrosine kinase inhibitors in patients with positive HBV serology (including those with active disease) and for patients who test positive for HBV during treatment\r\n*  Patients who are carriers of HBV who require treatment with BCR-ABL tyrosine kinase inhibitors should be closely monitored for signs and symptoms of active HBV infection throughout treatment and for several months after stopping\r\n*  Suspected adverse drug reactions to BCR-ABL tyrosine kinase inhibitors should be [reported to us on a Yellow Card](http://www.mhra.gov.uk/yellowcard)\r\n$CTA\r\n\r\nBCR-ABL tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, and ponatinib) are used in the treatment of chronic myeloid leukaemia or Philadelphia chromosome positive acute lymphoblastic leukaemia. Full details of authorised indications are given in individual Summaries of Product Characteristics.[^1]\r\n\r\n##Cases of HBV reactivation\r\n\r\nAn EU-wide review has shown that cases of HBV reactivation can occur in patients who are chronic carriers of the virus after they have received a BCR-ABL tyrosine kinase inhibitor. Some cases resulted in acute liver failure or fulminant hepatitis, leading to liver transplantation or death. The review assessed cases from clinical studies and cases of suspected adverse drug reactions reported by healthcare professionals and in the literature.\r\n\r\nCase reports suggest that HBV reactivation may occur at any time during treatment with a BCR-ABL tyrosine kinase inhibitor. Some patients had a history of hepatitis B, whereas for others the serological status at baseline was unknown. On HBV reactivation, an increase in viral load or positive serology was diagnosed.\r\n\r\nThe risk of HBV reactivation is considered a class effect of BCR-ABL tyrosine kinase inhibitors; however, the mechanism and frequency of virus reactivation during exposure are currently unknown.\r\n\r\n##Further information\r\n\r\n[InlineAttachment:tyrosine kinase inhibitors DHPC sent 11 April 2016.pdf] 11 April 2016 \r\n\r\nEU Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on [updates to product information for BCR-ABL tyrosine kinase inhibitors](http://www.ema.europa.eu/docs/en_GB/document_library/PRAC_recommendation_on_signal/2016/02/WC500202306.pdf)\r\n\r\n\r\nArticle citation: Drug Safety Update vol 9 issue 10, May 2016: 1.\r\n\r\n[^1]: Summaries of Product Characteristics are available on the [European Medicines Agency website](http://www.ema.europa.eu/ema/) for dasatinib, nilotinib, bosutinib, and ponatinib, and on the [MHRA website](http://www.mhra.gov.uk/spc-pil/?secLevelIndexChar=Im%20-%20Ip#retainDisplay) for imatinib.\r\n*[HBV]: hepatitis B virus "}],"max_cache_time":10,"attachments":[{"content_id":"d510de7c-0e2b-48db-b514-529995421dec","title":"Letter sent to healthcare professionals","url":"https://assets.digital.cabinet-office.gov.uk/media/5731b42be5274a037b000005/tyrosine_kinase_inhibitors_DHPC_sent_11_April_2016.pdf","updated_at":"2016-05-10T10:12:58Z","created_at":"2016-05-10T10:12:59Z","content_type":"application/pdf"}],"headers":[{"text":"Cases of HBV reactivation","level":2,"id":"cases-of-hbv-reactivation"},{"text":"Further information","level":2,"id":"further-information"}]},"routes":[{"path":"/drug-safety-update/bcr-abl-tyrosine-kinase-inhibitors-risk-of-hepatitis-b-reactivation","type":"exact"}],"redirects":[],"publishing_app":"specialist-publisher","rendering_app":"government-frontend","need_ids":[],"phase":"live","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","first_published_at":"2016-05-10T14:31:15Z","base_path":"/drug-safety-update/bcr-abl-tyrosine-kinase-inhibitors-risk-of-hepatitis-b-reactivation","description":"Patients should be tested for hepatitis B virus before starting treatment with BCR-ABL tyrosine kinase inhibitors.","content_id":"c0687f0e-f85b-4bd8-a98e-2c1cba5d33d7","locale":"en","expanded_links":{"organisations":[{"analytics_identifier":"EA63","api_path":"/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency","base_path":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","description":null,"document_type":"organisation","locale":"en","public_updated_at":"2015-06-29T14:33:29Z","schema_name":"placeholder","title":"Medicines and Healthcare products Regulatory Agency","withdrawn":false,"details":{"brand":"department-of-health","logo":{"formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","crest":"single-identity"}},"links":{}}],"finder":[{"analytics_identifier":null,"api_path":"/api/content/drug-safety-update","base_path":"/drug-safety-update","content_id":"602be505-4cf4-4f8c-8bfc-7bc4b63a7f47","description":"Find drug safety updates issued by MHRA","document_type":"finder","locale":"en","public_updated_at":"2017-03-30T10:34:00Z","schema_name":"finder","title":"Drug Safety Update","withdrawn":false,"details":{"document_noun":"update","filter":{"document_type":"drug_safety_update"},"format_name":"Drug Safety Update","show_summaries":true,"facets":[{"key":"therapeutic_area","name":"Therapeutic area","type":"text","preposition":"about","display_as_result_metadata":true,"filterable":true,"allowed_values":[{"label":"Anaesthesia and intensive care","value":"anaesthesia-intensive-care"},{"label":"Cancer","value":"cancer"},{"label":"Cardiovascular disease and lipidology","value":"cardiovascular-disease-lipidology"},{"label":"Dentistry","value":"dentistry"},{"label":"Dermatology","value":"dermatology"},{"label":"Ear, nose and throat","value":"ear-nose-throat"},{"label":"Endocrinology, diabetology and metabolism","value":"endocrinology-diabetology-metabolism"},{"label":"GI, hepatology and pancreatic disorders","value":"gi-hepatology-pancreatic-disorders"},{"label":"Haematology","value":"haematology"},{"label":"Immunology and vaccination","value":"immunology-vaccination"},{"label":"Immunosuppression and transplantation","value":"immunosuppression-transplantation"},{"label":"Infectious disease","value":"infectious-disease"},{"label":"Neurology","value":"neurology"},{"label":"Nutrition and dietetics","value":"nutrition-dietetics"},{"label":"Obstetrics, gynaecology and fertility","value":"obstetrics-gynaecology-fertility"},{"label":"Ophthalmology","value":"ophthalmology"},{"label":"Paediatrics and neonatology","value":"paediatrics-neonatology"},{"label":"Pain management and palliation","value":"pain-management-palliation"},{"label":"Psychiatry","value":"psychiatry"},{"label":"Radiology and imaging","value":"radiology-imaging"},{"label":"Respiratory disease and allergy","value":"respiratory-disease-allergy"},{"label":"Rheumatology","value":"rheumatology"},{"label":"Urology and nephrology","value":"urology-nephrology"}]},{"key":"first_published_at","name":"Published","short_name":"Published","type":"date","preposition":"published","display_as_result_metadata":true,"filterable":true}],"default_documents_per_page":50},"links":{}}],"available_translations":[{"title":"BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation","public_updated_at":"2016-05-10T14:31:14Z","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","base_path":"/drug-safety-update/bcr-abl-tyrosine-kinase-inhibitors-risk-of-hepatitis-b-reactivation","description":"Patients should be tested for hepatitis B virus before starting treatment with BCR-ABL tyrosine kinase inhibitors.","api_path":"/api/content/drug-safety-update/bcr-abl-tyrosine-kinase-inhibitors-risk-of-hepatitis-b-reactivation","withdrawn":false,"content_id":"c0687f0e-f85b-4bd8-a98e-2c1cba5d33d7","locale":"en"}]},"format":"specialist_document","navigation_document_supertype":"other","user_journey_document_supertype":"thing","email_document_supertype":"other","government_document_supertype":"other","payload_version":0}